ENLIVEN THERAPEUTICS INC. - COMMON STOCK

20.65

14-March-25 14:30:48

15 minutes delayed

Stocks

+0.36

+1.77%

Today's range

20.65 - 22.21

ISIN

N/A

Source

NASDAQ

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

28 Sep 2024 08:35:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

18 Sep 2024 15:05:07 By Nasdaq GlobeNewswire
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

13 Aug 2024 15:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics to Present at Two Upcoming Investor Conferences

29 May 2024 15:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

14 May 2024 15:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

11 Apr 2024 06:55:00 By Nasdaq GlobeNewswire
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

09 Apr 2024 15:05:00 By Nasdaq GlobeNewswire
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

28 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.